June 2026 Monthly Content Release Notes Copied

06/25/20262026 ContentContent releasePhysician, Clinical, Admin, Billing

Problem Groups

Updates

Curbside Connect with Dr. Andorsky on 2L+ LBCL patients is now available for scheduling in Diffuse Large B-cell Lymphoma.

Lab Analytes & Panels

Summary

There were 43 new panels created and 41 new analytes created for the June 2026 release.

Additions

  • % NK (CD56/16), %
  • Ab NK (CD56/16), /uL
  • Adaptive B-cell clonoSEQ clonality (ID) panel
  • Adaptive clonoSEQ tracking (MRD) panel
  • Adaptive T-cell clonoSEQ clonality (ID) panel
  • Ambry BRCANext panel
  • Ambry CancerNext panel
  • Ambry CustomNext panel
  • Ambry ProstateNext panel
  • Amikacin, trough, mg/L
  • AML MRD flow panel
  • Antibody screen, RBC w/refl id, titer and AG panel
  • Anti-etanercept antibody level, ng/mL
  • Azithromycin level, ug/mL
  • B-ALL MRD flow bone marrow panel
  • B-ALL MRD flow peripheral blood panel
  • Bullous pemphigoid bp180 ab, RU/mL
  • Centromere IgG, U/mL
  • DDAVP challenge profile interpretation
  • Etanercept and anti etanercept AB panel
  • Etanercept drug concentration, ug/mL
  • Ethambutol level, ug/ml
  • Factor VIII inhibitor, chromogenic screen
  • Ferret epithelium, IgE (E217), kU/L
  • Ferret epithelium, IgE E217 class
  • Ferret epithelium, IgE panel
  • Gentamicin, trough, mg/L
  • Guardant Complete Profiling + Monitoring
  • Guardant Liquid Profiling + Monitoring
  • Guardant MRD + Monitoring
  • Guardant Therapy Response Monitoring
  • Guardant360 Liquid CDx
  • HGB A1c with eAG, calc panel
  • HGB A1c with eAG, calc, mg/dL
  • Histoplasma galactomannan antigen EIA, urine
  • Histoplasma galactomannan antigen EIA, urine panel
  • Histoplasma Gal’mannan Ag Qn U, ng/mL
  • HIV-2 RNA PCR, qual
  • HPV 16 RNA, cervical
  • HPV 16 RNA, vaginal
  • HPV 18/45 RNA, cervical
  • HPV 18/45 RNA, vaginal
  • JO-1 IgG, U/mL
  • KIT D816V mutation, mastocytosis/AML, quant ddPCR
  • LabCorp OmniSeq INSIGHT panel
  • M Spike 1, %
  • M Spike 2, %
  • M Spike, %
  • Monkeypox (orthopoxvirus), PCR
  • Mycoplasma genitalium, rRNA, TMA
  • Ova and parasites, concentrate and permanent smear
  • Protein, total, 24 hr urine panel w/creatinine
  • Quest haystackMRD baseline panel
  • Quest HaystackMRD baseline panel
  • Quest haystackMRD monitoring panel
  • Quest HaystackMRD monitoring panel
  • Quest LiquidSEQ panel (523 gene NGS Profile)
  • Quest LiquidSEQ panel (523 gene NGS Profile)
  • Quest LungSEQ panel
  • Quest LungSEQ panel
  • Quest Oncomine Dx target test panel
  • Quest Oncomine™ Dx target test
  • Quest solid tumor core panel (49-gene NGS profiling)
  • Quest solid tumor core panel (49-gene NGS profiling)
  • Quest solid tumor expanded panel (523-gene NGS profiling)
  • Quest solid tumor expanded panel (523-gene NGS profiling)
  • RNP U1 IgG, U/mL
  • SCL-70 IgG
  • Smith IgG, U/mL
  • SS-A/ro IgG, U/mL
  • SS-B/La IgG, U/mL
  • Tempus xF plus addendum report panel
  • Tempus xF plus amendment report panel
  • Tempus xF plus report panel
  • Teriflunomide, ng/mL
  • Titanium panel
  • Titanium, WB, ng/mL
  • T-Lymphocyte CD3 cells panel
  • Tobramycin, peak level, mg/L
  • Tobramycin, trough level, mg/L
  • T-spot negative control
  • T-spot positive control
  • Vancomycin, mg/L
  • von Willebrand disease panel with collagen binding assay (CBA)

Medications

Additions

  • American ginseng (Panax quinquefolius) Oral
  • Atebimetinib invest Oral
  • Blood Builder Iron Supplement Oral
  • Calcium Folinate invest IV
  • Hyaluronic Acid External Gel Cream
  • Ivonescimab or Bevacizumab invest IV
  • JANX014 invest IV
  • LY4584180 invest Oral
  • NKT5097 invest Oral
  • TAK-505 invest IV

Updates

Medications Updates
[F-8]-FAPI-74 invest IV Updated Name:

  • [F-18]-FAPI-74 invest IV

Updated Form:

  • 1 mCi-110mCi/mL in 6 mL syringe
Aromasin (Exemestane Oral)

Tamoxifen Oral

 The Dispense Quantity field is left blank, allowing users to enter the preferred value.
GPX-001 invest IV New Name available:

  • Quaratusugene ozeplasmid (REQORSA) invest IV
GS-1811 invest IV New Name available:

  • Denikitug invest (GS-1811 invest IV)
HMBD-501 (ENV-501) invest IV Instructions removed:

  • Do not shake. Do not administer study drug as an intravenous push or bolus. See Pharmacy Manual for preparation, handling, and administration, observation guidance.
LY4337713 invest IV New SIG available:

  • 16 GBq intravenously once
NX-5948 invest Oral Updated Name:

  • NX-5948 (Bexobrutideg) invest Oral

New SIG available:

  • 0 mg orally daily

New Form available:

  • 100 mg capsule
PF-08634404 or Bevacizumab invest IV New SIG available:

  • 0 mL intravenously once
  • 100 mL intravenously once

New Form available:

  • 100 mg solution
Pyridoxine Hydrochloride / Tirzepatide New SIG available:

  • 10 units subcutaneously every week

New Form available:

  • 25 mg/18 mg/mL solution
Teclistamab-cqyv Subcutaneous Removed Maximum Single Dose:

  • 225 mg

New Maximum Single Dose available:

  • 450 mg
Yuvafem (Estradiol Vaginal Tablet) New SIG available:

  • Estradiol 10 mcg vaginally As Directed; Insert 1 tablet vaginally daily x 14 days, then 1 tablet twice weekly (e.g., Tue & Fri)
  • Estradiol 10 mcg vaginally As Directed; Insert 1 tablet vaginally twice weekly (e.g., Tue & Fri)

Regimen Library

Additions

Regimen Name Diagnosis
Abemaciclib + Anastrozole + Leuprolide Q3M Breast Cancer
Abemaciclib + Exemestane + Leuprolide Q3M Breast Cancer
Abemaciclib + Letrozole + Leuprolide Q3M Breast Cancer
Abemaciclib + Tamoxifen + Leuprolide Q3M Breast Cancer
Carvykti (Ciltacabtagene Autoleucel IV) Multiple Myeloma (MM)
MATRix Q21D Lymphoma, Non-Hodgkin (NHL) (Parent)
Ribociclib D1-21 + Anastrozole + Goserelin Q3M (Adjuvant) Breast Cancer
Ribociclib D1-21 + Anastrozole + Leuprolide Q3M (Adjuvant) Breast Cancer
Ribociclib D1-21 + Letrozole + Goserelin Q3M (Adjuvant) Breast Cancer
Ribociclib D1-21 + Letrozole + Leuprolide Q3M (Adjuvant) Breast Cancer
Rituximab IV D1,15 (1000 mg) Q6M Autoimmune (Parent); Autoimmune, Other; Systemic Lupus Erythematosus
Yescarta (Axicabtagene Ciloleucel IV) Lymphoma, Non-Hodgkin (NHL) (Parent)

Updates

  • Anal Cancer (Parent)
  • Bile Duct Cancer (Parent)
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Head and Neck Cancer (Parent)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Malignant Mesothelioma
  • Malignant Pleural Mesothelioma
  • Myelodysplastic Syndrome (MDS)
  • Myelofibrosis
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Uterine Cancer (Parent)

Renames

Previous Name New Name
Dostarlimab-gxly + Paclitaxel + Carboplatin Q21D Dostarlimab + Paclitaxel + Carboplatin Q21D
Fluorouracil CIV D1-5 + Cisplatin + Tislelizumab-jsgr Q21D Fluorouracil CIV D1-5 + Cisplatin + Tislelizumab Q21D
Leuprolide Q28D (Ovarian, Uterine) Leuprolide Q28D (Ovarian)
Luspatercept-aamt Q21D (MDS, Myelofibrosis) Luspatercept Q21D (MDS, Myelofibrosis)
Tremelimumab-actl + Durvalumab + Abraxane D1,8,15 + Carboplatin Q21D Tremelimumab + Durvalumab + Abraxane D1,8,15 + Carboplatin Q21D

Removals

Regimen Name Diagnosis
Cladribine CIV D1-7 Leukemia, Hairy Cell; Leukemia, Chronic Lymphocytic (CLL)
Nivolumab + Paclitaxel + Cisplatin Q21D (Neoadjuvant NSCLC) Lung Cancer, Non-small Cell (NSCLC);
Thalidomide +/- Prednisone Q28D Myelofibrosis

Billing & HCPCS Codes

Additions

Medication HCPCS Codes
Amivantamab-Hyaluronidase-lpuj Subcutaneous

 

 J9062

  • per 5 mg
  • Per 0.03125 mL
Apraclonidine Ophthalmic Drops 1 % J2374 per 1 dose
Belantamab Mafodotin-blmf IV J9053 per 0.1 mg
Denosumab-desu Subcutaneous (60 mg/mL – Osvyrti) Q5165 per 1 mg
Denosumab-desu Subcutaneous (120 mg/1.7 mL – Jubereq) Q5166 per 1 mg
Denosumab-qbde Subcutaneous (60 mg/mL – Enoby) Q5167 per 1 mg
Denosumab-qbde Subcutaneous (120 mg/1.7 mL – Xtrenbo) Q5167 per 1 mg
Depemokimab-ulaa Subcutaneous J2361 per 1 mg
Docetaxel IV J9232 per 1 mg
Ferumoxytol IV (Ferabright) A9574 per 1 mg
Fibrinogen, Human-chmt IV J7176 per 1 mg
Fosfomycin IV J0528 per 20 mg
Immune Globulin, Gamma (IgG)-kthm IV J1577 per 100 mg
Narsoplimab-wuug IV J1289 per 1 mg
Onasemnogene Abeparvovec-brve J3405 per 1 dose
Ustekinumab-hmny IV Q5164 per 1 mg
Ustekinumab-hmny Subcutaneous Q5164 per 1 mg

Therapeutic Interchange Management

Details about recent content updates for Therapeutic Interchange Management content groups can be found on the Ontada Guide Site.

Professional Services

Additions

The following codes and descriptions will be effective July 1, 2026.

Code Description
G0572 Management of new patient with dementia residing in an eligible memory care unit, for use only in a Medicare-approved CMMI model (services must be furnished within a patient’s eligible memory care unit, including specialized dementia care units within assisted living facilities or other qualifying memory care settings designed to provide specialized care for individuals with dementia and cognitive impairment)
G0669 Outcome-aligned payment (OAP) for technology-enabled chronic care management of early cardio-kidney-metabolic (ECKM) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); initial 12-month period; per month
G0573

 

 Management of established patient with dementia residing in an eligible memory care unit, for use only in a Medicare-approved CMMI model (services must be furnished within a patient’s eligible memory care unit, including specialized dementia care units within assisted living facilities or other qualifying memory care settings designed to provide specialized care for individuals with dementia and cognitive impairment)
G0574

 

 Management of new patient with dementia residing in an eligible residential care community, for use only in a Medicare-approved CMMI model (services must be furnished within a patient’s eligible residential care community, including assisted living facilities, board and care homes, or other qualifying residential settings where dementia care services are provided)
G0575 Management of established patient with dementia residing in an eligible residential care community, for use only in a Medicare-approved CMMI model (services must be furnished within a patient’s eligible residential care community, including assisted living facilities, board and care homes, or other qualifying residential settings where dementia care services are provided)
G0670

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of early cardio-kidney-metabolic (ECKM) conditions (hypertension, or two or more of: dyslipidemia, obesity/overweight with central obesity marker, prediabetes); follow-on 12-month period; per month
G0671

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of cardio-kidney-metabolic (CKM) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); initial 12-month period; per month
G0672

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of cardio-kidney-metabolic (CKM) conditions (one or more of: diabetes mellitus, chronic kidney disease stage 3a or 3b, atherosclerotic cardiovascular disease); follow-on 12-month period; per month
G0676

 

 Standard co-management service payment for documented review of clinical updates from access participant managing cardio-kidney-metabolic conditions (early cardio-kidney-metabolic [ECKM] or cardio-kidney-metabolic [CKM] track); per review
G0673

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of musculoskeletal (MSK) conditions (chronic musculoskeletal pain); initial 12-month treatment period; per month
G0674

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of behavioral health (BH) conditions (one or more of: depression, anxiety); initial 12-month period; per month
G0675

 

 Outcome-aligned payment (OAP) for technology-enabled chronic care management of behavioral health (BH) conditions (one or more of: depression, anxiety); follow-on 12-month period; per month
G0677 Standard co-management service payment for documented review of clinical updates from access participant managing musculoskeletal (MSK) conditions; per review
G0678

 

 Standard co-management-management service payment for documented review of clinical updates from access participant managing behavioral health (BH) conditions (depression, anxiety); per review
G0685

 

 Algorithmic analysis for identification of new lesions and determination of change of existing lesions for advanced metastatic cancer using data sets from two or more previously acquired pet or pet/ct studies
M0231

 

 Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, first dose
M0232

 

 Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose